EUVIMEDEUVIMED entdecken
Open Access

Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers

Angelina T Regua, Shivani Bindal, Mariana K Najjar, Chuling Zhuang, Munazza Khan, Austin B J Arrigo, Anneliese O Gonzalez, Xinhai R Zhang, Jay-Jiguang Zhu, Kounosuke Watabe, Hui-Wen Lo

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.217023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Angelina T Regua und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; Grad…. Hauptthemen laut MEDLINE: Janus Kinase 2, Triple Negative Breast Neoplasms, Benzamides, Pyrimidines. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, US Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Triple Negative Breast NeoplasmsBenzamidesPyrimidinesErb-b2 Receptor Tyrosine KinasesReceptor, trkAXenograft Model Antitumor AssaysHumansAnimalsFemaleCell Line, TumorMiceCell ProliferationIndazolesPyrazolesSignal TransductionAntineoplastic Combined Chemotherapy ProtocolsApoptosisProtein Kinase InhibitorsMice, NudeDrug SynergismBridged-Ring Compounds

Stichwörter der Autor:innen

Breast cancerBreast cancer metastasisCombined targeted therapyJAK2TrkA

Substanzen

Janus Kinase 2BenzamidesPyrimidinesErb-b2 Receptor Tyrosine KinasesReceptor, trkAIndazolesPyrazolesProtein Kinase InhibitorsBridged-Ring Compoundsentrectinib

Autor:innen und Institutionen

  • Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas Health Sci…
  • Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Department of Pathology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
  • Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • US Department of Defense
  • American Association for Cancer Research
  • METAvivor

Zitieren

APA

Regua, A. T., Bindal, S., Najjar, M. K., Zhuang, C., Khan, M., Arrigo, A. B. J., Gonzalez, A. O., Zhang, X. R., Zhu, J. J., Watabe, K., & Lo, H. W. (2024). Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217023

Vancouver

Regua AT, Bindal S, Najjar MK, Zhuang C, Khan M, Arrigo ABJ, et al. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217023

BibTeX
@article{Regua2024,
  author = {Regua, Angelina T and Bindal, Shivani and Najjar, Mariana K and Zhuang, Chuling and Khan, Munazza and Arrigo, Austin B J and Gonzalez, Anneliese O and Zhang, Xinhai R and Zhu, Jay-Jiguang and Watabe, Kounosuke and Lo, Hui-Wen},
  title = {Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.217023}
}
Kostenlos starten →